Lerman Tsahi T, Levi Amos, Jørgensen Troels Højsgaard, Søndergaard Lars, Talmor-Barkan Yeela, Kornowski Ran
Department of Internal Medicine F-Recanati, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.
Department of Cardiology, Rabin Medical Center, Petah Tikva, Israel.
Front Cardiovasc Med. 2023 Sep 13;10:1242608. doi: 10.3389/fcvm.2023.1242608. eCollection 2023.
BACKGROUND: This study aims to compare valve durability between transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR). METHODS: We conducted a systematic review and meta-analysis using data from randomized controlled trials (RCTs). The primary outcome was structural valve deterioration (SVD). Secondary outcomes were bioprosthetic valve failure, reintervention, effective orifice area (EOA), mean pressure gradient, and moderate-severe aortic regurgitation (AR, transvalvular and/or paravalvular). RESULTS: Twenty-five publications from seven RCTs consisting of 7,970 patients were included in the analysis with follow-up ranges of 2-8 years. No significant difference was found between the two groups with regard to SVD [odds ratio (OR) 0.72; 95% CI: 0.25-2.12]. The TAVI group was reported to exhibit a statistically significant higher risk of reintervention (OR 2.03; 95% CI: 1.34-3.05) and a moderate-severe AR (OR 6.54; 95% CI: 3.92-10.91) compared with the SAVR group. A trend toward lower mean pressure gradient in the TAVI group [(mean difference (MD) -1.61; 95% CI: -3.5 to 0.28)] and significant higher EOA (MD 0.20; 95% CI: 0.08-0.31) was noted. CONCLUSION: The present data indicate that TAVI provides a comparable risk of SVD with favorable hemodynamic profile compared with SAVR. However, the higher risk of significant AR and reintervention was demonstrated. SYSTEMATIC REVIEW REGISTRATION: PROSPERO (CRD42022363060).
背景:本研究旨在比较经导管主动脉瓣植入术(TAVI)和外科主动脉瓣置换术(SAVR)之间瓣膜的耐久性。 方法:我们使用来自随机对照试验(RCT)的数据进行了系统评价和荟萃分析。主要结局是结构性瓣膜退变(SVD)。次要结局包括生物瓣膜失效、再次干预、有效瓣口面积(EOA)、平均压力阶差以及中重度主动脉瓣反流(AR,经瓣和/或瓣周)。 结果:分析纳入了来自7项RCT的25篇文献,共7970例患者,随访时间为2至8年。两组在SVD方面无显著差异[比值比(OR)0.72;95%置信区间(CI):0.25 - 2.12]。据报道,与SAVR组相比,TAVI组再次干预的风险具有统计学意义的更高(OR 2.03;95% CI:1.34 - 3.05),且中重度AR的风险也更高(OR 6.54;95% CI:3.92 - 10.91)。注意到TAVI组平均压力阶差有降低趋势[平均差值(MD) - 1.61;95% CI: - 3.5至0.28],而EOA显著更高(MD 0.20;95% CI:0.08 - 0.31)。 结论:目前的数据表明,与SAVR相比,TAVI发生SVD的风险相当,且血流动力学特征良好。然而,TAVI显示出显著AR和再次干预的风险更高。 系统评价注册:PROSPERO(CRD42022363060)
Cochrane Database Syst Rev. 2019-12-20
J Am Coll Cardiol. 2019-2-12
JAMA Cardiol. 2017-11-1
Interdiscip Cardiovasc Thorac Surg. 2025-8-5
Cardiovasc Eng Technol. 2025-2-5
Nat Rev Cardiol. 2024-1
Front Cardiovasc Med. 2023-5-9
Front Cardiovasc Med. 2022-11-21
J Am Coll Cardiol. 2022-3-8